💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Atorvastatin

CHEMBL1487 Phase 4 معتمد Small molecule
Half-Life
14 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
558.6 g/mol
LogP
5.0
Phase
4

A statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, substantially lowering LDL cholesterol levels and reducing the risk of heart attack and stroke. It is one of the most widely prescribed medications worldwide.

الوزن الجزيئي

558,6400 g/mol

LogP

5,00

TPSA

112,00 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Endometriosis Cardiovascular Disease Age-Related Macular Degeneration Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Asthma Chronic Obstructive Pulmonary Disease Alzheimer's Disease Epilepsy Migraine Melanoma Inflammatory Bowel Disease Psoriasis Systemic Lupus Erythematosus Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Hyperlipidemia Obesity Lymphoma Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Chronic Pain HIV/AIDS Hepatitis C Tuberculosis Heart Failure Atrial Fibrillation Prostate Cancer Colorectal Cancer Leukemia

تصنيفات الأدوية

C — C - Cardiovascular System

آلية العمل

Competitive inhibitor of HMG-CoA reductase.

Pharmacokinetics (PK)

Half-Life 14 hours

Pharmacodynamics (PD)

الآلية

Competitive inhibitor of HMG-CoA reductase.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C33H35FN2O5

                    

                    
                    

                        
HBD / HBA

                        
4 / 6

                    

                    
                    

                        
الروابط القابلة للدوران

                        
12

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
41

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            HMGCR (HMG-CoA Reductase)
                            Inhibitor
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            CYP3A4 (Cytochrome P450 3A4)
                            Substrate
                        

                        
                    

                    
                    

                        

                            ABCB1 (P-glycoprotein)
                            Substrate
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Major


                            
                                Atorvastatin + Cyclosporine
                            
                        

                        
                        
Cyclosporine dramatically increases atorvastatin plasma levels through combined inhibition of CYP3A4, OATP1B1, and P-gp, substantially raising the risk of myopathy and rhabdomyolysis.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Atorvastatin + Doxycycline
                            
                        

                        
                        
Doxycycline may slightly raise atorvastatin plasma levels through weak inhibition of CYP3A4 and P-glycoprotein, though clinically significant myopathy from this combination is rarely reported.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Atorvastatin + Diltiazem
                            
                        

                        
                        
Diltiazem inhibits CYP3A4-mediated atorvastatin metabolism, increasing atorvastatin plasma concentrations and the risk of myopathy and rhabdomyolysis.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Atorvastatin + Amlodipine
                            
                        

                        
                        
Amlodipine weakly inhibits CYP3A4-mediated atorvastatin metabolism, leading to a modest increase in atorvastatin exposure; the combination is generally used safely in clinical practice.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
A statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, substantially lowering LDL cholesterol levels and reducing the risk of heart attack and stroke. It is one of the most widely prescribed medications worldwide.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Competitive inhibitor of HMG-CoA reductase.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Atorvastatin: Half-life: 14 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Atorvastatin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            
            

                
                
                    ADME Journey →
                
                
                
            

            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Amlodipine
                            Small molecule
                        
                        
                        
                            Lisinopril
                            Small molecule
                        
                        
                        
                            Metoprolol
                            Small molecule
                        
                        
                        
                            Losartan
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1487.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 60823.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.